Avedro, Inc., a pioneering name in the ophthalmic industry, is headquartered in the United States and operates extensively across major regions, including North America and Europe. Founded in 2000, Avedro has made significant strides in the field of corneal cross-linking, a revolutionary treatment for keratoconus and other corneal disorders. The company’s flagship products, including the KXL System and the proprietary riboflavin solutions, are distinguished by their innovative approach to strengthening corneal tissue, thereby enhancing patient outcomes. Avedro's commitment to advancing eye care has positioned it as a leader in the market, with notable achievements such as FDA approvals and a growing global presence. Through its cutting-edge technology and dedication to research, Avedro continues to shape the future of ophthalmology.
We don't have data for Avedro, Inc., but we can show you information about their parent organization instead.
View parent company